Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415467 · ClinicalTrials.gov registry record · Phase 4
Treatment of Resectable Malignant Brain Tumors
A Phase 4 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00415467: Clinical Trial Phase 4 study, sponsored by M.D. Anderson Cancer Center.
NCT00415467 is a Phase 4 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415467, a Phase 4 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
The goals of this study are to evaluate each of the following items: 1. Time to recurrence in patients receiving brachytherapy with the GliaSite RTS 2. Overall survival (OS) in patients with malignant brain tumors who are undergoing surgical resection and brachytherapy treatment with the GliaSite® Radiation Therapy System (RTS). 3. Incidence of serious adverse events in patients treated with GliaSite RTS
Interventions
- DEVICE GliaSite Radiation Therapy System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415467
The ClinicalTrials.gov registry entry for NCT00415467 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GliaSite Radiation Therapy System is the first listed.
NCT00415467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415467 about?
NCT00415467 is a clinical study titled "Treatment of Resectable Malignant Brain Tumors". The goals of this study are to evaluate each of the following items: 1. Time to recurrence in patients receiving brachytherapy with the GliaSite RTS 2. Overall survival (OS) in patients with malignant brain tumors who are undergoing surgical resection and brachytherapy treatment with the GliaSite® ...
What is the current status of trial NCT00415467?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2005-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00415467?
The interventions under investigation include: GliaSite Radiation Therapy System (DEVICE).
Who is sponsoring clinical trial NCT00415467?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.